Novartis Ag (NVS) Common Equity (2009 - 2026)
Novartis Ag (NVS) posted Common Equity of $41.9 billion for Q2 2026, up 7.76% sequentially from $38.9 billion in Q1 2026, and little changed YoY from $42.1 billion in Q2 2025.
Novartis Ag (NVS) Common Equity (2009 - 2026) Analysis & Trends
Novartis Ag has reported Common Equity for 18 years, with the latest figure at $41.9 billion in Q2 2026.
- Quarterly Common Equity changed 0.26% year-over-year to $41.9 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $41.9 billion (changed 0.26% YoY) and the FY2025 annual result came in at $46.5 billion, up 5.49% from the prior year.
- Common Equity improved to $41.9 billion in Q2 2026 per NVS's latest filing, from $38.9 billion in the prior quarter.
- Over five years, Common Equity peaked at $61.7 billion in Q1 2022 and troughed at $766.0 million in Q3 2025.
- A 5-year average of $33.9 billion and a median of $41.9 billion in 2024 frame the typical range for Common Equity.
- The sharpest annual moves came in 2023 and 2024: Common Equity jumped 5031.52% in 2023, then dropped 23.75% in 2024.
- Over 5 years, Common Equity stood at $59.4 billion in 2022, then retreated by 21.33% to $46.8 billion in 2023, then slipped by 5.61% to $44.1 billion in 2024, then gained by 5.49% to $46.5 billion in 2025, then dropped by 9.89% to $41.9 billion in 2026.
- According to Business Quant data, Common Equity over the past three periods registered $41.9 billion, $38.9 billion, and $46.5 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | 84.97 Bn |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | -5.94 Bn |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | 106.07 Bn |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | 41.95 Bn |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | 50.37 Bn |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | 11.69 Bn |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | 11.83 Bn |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 85.49 Bn |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | 23.05 Bn |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn | 80.86 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 41.95 Bn |
| Mar 31, 2026 | 38.93 Bn |
| Dec 31, 2025 | 46.55 Bn |
| Sep 30, 2025 | 766.00 Mn |
| Jun 30, 2025 | 42.05 Bn |
| Mar 31, 2025 | 38.45 Bn |
| Dec 31, 2024 | 44.13 Bn |
| Sep 30, 2024 | 793.00 Mn |
| Jun 30, 2024 | 41.90 Bn |
| Mar 31, 2024 | 39.76 Bn |
| Dec 31, 2023 | 46.75 Bn |
| Sep 30, 2023 | 825.00 Mn |
| Jun 30, 2023 | 51.93 Bn |
| Mar 31, 2023 | 52.14 Bn |
| Dec 31, 2022 | 59.42 Bn |
| Sep 30, 2022 | 890.00 Mn |
| Jun 30, 2022 | 1.01 Bn |
| Mar 31, 2022 | 61.70 Bn |
| Dec 31, 2021 | 67.82 Bn |
| Sep 30, 2021 | 901.00 Mn |